Associations of human leukocyte antigen class II genotypes with human papillomavirus 18 infection and cervical intraepithelial neoplasia risk

Cancer

Volumn 118, Issue 1, 2012, Pages 223-231

  Chuang, Li Chung ^a,b   Hu, Chung Yi ^c   Chen, Hui Chi ^b,c   Lin, Pei Jung ^d   Lee, Borheng ^e   Lin, Ching Yu ^f   Pan, Mei Hung ^b,c   You, San Lin ^b,c   Hsieh, Chang Yao ^d   Chen, Chien Jen ^b,c  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b GENOMICS RESEARCH CENTER   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e Yuan Shan Research Institute   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

cervical neoplasia; high grade squamous intraepithelial lesions; human leukocyte antigen class II; human papillomavirus type 18; longitudinal study; persistent infection

Indexed keywords

HLA ANTIGEN CLASS 2; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN;

ADULT; AGED; ALLELE; ARTICLE; CANCER GRADING; CANCER RISK; COHORT ANALYSIS; COMMUNITY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 18; MAJOR CLINICAL STUDY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UTERINE CERVIX CARCINOMA IN SITU; VIRUS LOAD;

CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT STUDIES; FEMALE; GENOTYPE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA ANTIGENS; HUMAN PAPILLOMAVIRUS 18; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; RISK FACTORS; VIRAL LOAD;

EID: 83855162910     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26227     Document Type: Article

References (32)

1. Munoz N,. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol. 2000; 19: 1-5.
2. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV,. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002; 55: 244-265. (Pubitemid 34293391)
3. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens-pt B: biological agents. Lancet Oncol. 2009; 10: 321-322.
4. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12-19. (Pubitemid 29406813)
5. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H,. Classification of papillomaviruses. Virology. 2004; 324: 17-27. (Pubitemid 38737395)
6. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348: 518-527. (Pubitemid 36159887)
7. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007; 121: 621-632. (Pubitemid 46986496)
8. Bao YP, Li N, Smith JS, Qiao YL,. Human papillomavirus type distribution in women from Asia: a meta-analysis. Int J Gynecol Cancer. 2008; 18: 71-79.
9. Liaw KL, Hsing AW, Schiffman MH, et al. Human papillomavirus types 52 and 58 are prevalent in cervical cancer from Chinese women. Int J Cancer. 1997; 73: 775-776.
10. Lin H, Ma YY, Moh JS, Ou YC, Shen SY, ChangChien CC,. High prevalence of genital human papillomavirus type 52 and 58 infection in women attending gynecologic practitioners in South Taiwan. Gynecol Oncol. 2006; 101: 40-45.
11. Ding DC, Hsu HC, Huang RL, et al. Type-specific distribution of HPV along the full spectrum of cervical carcinogenesis in Taiwan: an indication of viral oncogenic potential. Eur J Obstet Gynecol Reprod Biol. 2008; 140: 245-251.
12. Chen HC, You SL, Hsieh CY, et al. Prevalence of genotype-specific human papillomavirus infection and cervical neoplasia in Taiwan: a community-based survey of 10,602 women. Int J Cancer. 2010; 128: 1192-1203.
13. Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA. 2001; 286: 3106-3114. (Pubitemid 34016525)
14. Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS,. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol. 2008; 168: 123-137. (Pubitemid 351951589)
15. Rodriguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst. 2008; 100: 513-517.
16. Hildesheim A, Wang SS,. Host and viral genetics and risk of cervical cancer: a review. Virus Res. 2002; 89: 229-240. (Pubitemid 35351541)
17. Beskow AH, Moberg M, Gyllensten UB,. HLA class II allele control of HPV load in carcinoma in situ of the cervix uteri. Int J Cancer. 2005; 117: 510-514. (Pubitemid 41429577)
18. Beskow AH, Gyllensten UB,. Host genetic control of HPV 16 titer in carcinoma in situ of the cervix uteri. Int J Cancer. 2002; 101: 526-531.
19. Maciag PC, Schlecht NF, Souza PS, Rohan TE, Franco EL, Villa LL,. Polymorphisms of the human leukocyte antigen DRB1 and DQB1 genes and the natural history of human papillomavirus infection. J Infect Dis. 2002; 186: 164-172. (Pubitemid 34765503)
20. Mahmud SM, Robinson K, Richardson H, et al. HLA polymorphisms and cervical human Papillomavirus infection in a cohort of Montreal University students. J Infect Dis. 2007; 196: 82-90. (Pubitemid 46982741)
21. Huang HJ, Huang SL, Lin CY, et al. Human papillomavirus genotyping by a polymerase chain reaction-based genechip method in cervical carcinoma treated with neoadjuvant chemotherapy plus radical surgery. Int J Gynecol Cancer. 2004; 14: 639-649. (Pubitemid 39062921)
22. Lin CY, Chen HC, Lin RW, et al. Quality assurance of genotyping array for detection and typing of human papillomavirus. J Virol Methods. 2007; 140: 1-9.
23. Lin CY, Chao A, Yang YC, et al. Human papillomavirus typing with a polymerase chain reaction-based genotyping array compared with type-specific PCR. J Clin Virol. 2008; 42: 361-367.
24. Jee SH, Tsai TF, Tsai WL, Liaw SH, Chang CH, Hu CY,. HLA-DRB1*0701 and DRB1*1401 are associated with genetic susceptibility to psoriasis vulgaris in a Taiwanese population. Br J Dermatol. 1998; 139: 978-983.
25. Hu CY, Wu CS, Lee CS, et al. HLA-DR11 and HLA-DR2 are negatively associated with autoantibody production in chronic hepatitis C. Ann Rheum Dis. 2006; 65: 138-139.
26. Huang YW, Hu CY, Chen CL, et al. Human leukocyte antigen-DRB1*1101 correlates with less severe hepatitis in Taiwanese male carriers of hepatitis B virus. J Med Virol. 2009; 81: 588-593.
27. Bodmer JG, Marsh SG, Albert ED, et al. Nomenclature for factors of the HLA system, 1995. Tissue Antigens. 1995; 46: 1-18.
28. Santamaria P, Boyce-Jacino MT, Lindstrom AL, Barbosa JJ, Faras AJ, Rich SS,. Detection of novel sequence heterogeneity and haplotypic diversity of HLA class II genes. Immunogenetics. 1991; 33: 374-387.
29. Bland JM, Altman DG,. Multiple significance tests: the Bonferroni method. BMJ. 1995; 310: 170.
30. Yang YC, Chang TY, Lee YJ, et al. HLA-DRB1 alleles and cervical squamous cell carcinoma: experimental study and meta-analysis. Hum Immunol. 2006; 67: 331-340.
31. Chan PK, Cheung TH, Lin CK, et al. Association between HLA-DRB1 polymorphism, high-risk HPV infection and cervical neoplasia in southern Chinese. J Med Virol. 2007; 79: 970-976. (Pubitemid 46871556)
32. Chan PK, Cheung JL, Cheung TH, et al. HLA-DQB1 polymorphisms and risk for cervical cancer: a case-control study in a southern Chinese population. Gynecol Oncol. 2007; 105: 736-741. (Pubitemid 46738579)